Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:COYA NASDAQ:TCRX NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$5.10-1.5%$4.52$1.80▼$20.83$26.66M-0.79116,028 shs64,133 shsCOYACoya Therapeutics$6.09+2.4%$5.86$4.65▼$10.24$99.51M0.2683,647 shs39,841 shsTCRXTScan Therapeutics$1.62-6.9%$1.64$1.02▼$6.81$98.47M0.99313,221 shs462,376 shsZURAZura Bio$1.50+7.1%$1.28$0.97▼$5.07$95.72M-0.06966,579 shs471,118 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate-1.54%-7.27%+17.51%+18.06%+1,344.35%COYACoya Therapeutics+2.35%-8.70%+5.36%-4.40%-11.22%TCRXTScan Therapeutics-6.90%-16.06%+10.20%+1.25%-77.31%ZURAZura Bio+7.14%-8.54%+33.93%+2.04%-62.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCINGCingulate3.207 of 5 stars3.55.00.00.03.20.80.6COYACoya Therapeutics1.957 of 5 stars3.53.00.00.01.90.80.0TCRXTScan Therapeutics3.1587 of 5 stars3.55.00.00.00.63.30.6ZURAZura Bio3.6303 of 5 stars3.65.00.00.03.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 3.00Buy$26.00409.80% UpsideCOYACoya Therapeutics 3.00Buy$16.50170.94% UpsideTCRXTScan Therapeutics 3.00Buy$7.80381.48% UpsideZURAZura Bio 3.13Buy$14.33855.56% UpsideCurrent Analyst Ratings BreakdownLatest CING, ZURA, COYA, and TCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.007/9/2025COYACoya TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/1/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/9/2025COYACoya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.005/13/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/9/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.005/7/2025TCRXTScan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.005/6/2025TCRXTScan TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$2.32 per shareN/ACOYACoya Therapeutics$3.69M27.64N/AN/A$2.37 per share2.57TCRXTScan Therapeutics$2.82M32.51N/AN/A$4.26 per share0.38ZURAZura BioN/AN/AN/AN/A$2.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)COYACoya Therapeutics-$14.88M-$1.07N/AN/AN/AN/A-48.88%-43.32%8/11/2025 (Estimated)TCRXTScan Therapeutics-$127.50M-$1.09N/AN/AN/A-2,974.08%-55.76%-36.56%8/11/2025 (Estimated)ZURAZura Bio-$45.39M-$0.70N/AN/AN/AN/A-42.84%-35.22%8/12/2025 (Estimated)Latest CING, ZURA, COYA, and TCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CINGCingulate-$0.82N/AN/AN/AN/AN/A8/12/2025Q2 2025ZURAZura Bio-$0.19N/AN/AN/AN/AN/A8/11/2025Q2 2025COYACoya Therapeutics-$0.22N/AN/AN/AN/AN/A8/11/2025Q2 2025TCRXTScan Therapeutics-$0.28N/AN/AN/A$1.31 millionN/A5/13/2025Q1 2025COYACoya Therapeutics-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million5/12/2025Q1 2025TCRXTScan Therapeutics-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/A5/8/2025Q1 2025ZURAZura Bio-$0.17-$0.19-$0.02-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulate0.161.871.87COYACoya TherapeuticsN/A8.848.84TCRXTScan Therapeutics0.158.558.55ZURAZura BioN/A8.148.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%COYACoya Therapeutics39.75%TCRXTScan Therapeutics82.83%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipCINGCingulate5.27%COYACoya Therapeutics12.00%TCRXTScan Therapeutics4.35%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate205.15 million4.88 millionNot OptionableCOYACoya Therapeutics616.73 million14.72 millionNot OptionableTCRXTScan Therapeutics10056.59 million54.13 millionNot OptionableZURAZura Bio368.38 million58.65 millionOptionableCING, ZURA, COYA, and TCRX HeadlinesRecent News About These CompaniesRobert Lisicki on Living Up to Zura Bio’s Heroic NamesakeJuly 31 at 2:47 AM | pharmexec.comP3 Penny Stocks With Market Caps Over $70M Worth WatchingJuly 18, 2025 | finance.yahoo.comZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | finance.yahoo.comZura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by AnalystsJuly 13, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Trading 12.5% Higher - Here's What HappenedJuly 10, 2025 | marketbeat.comZura Bio Announces Chief Financial Officer TransitionJuly 1, 2025 | businesswire.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comZura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025 | businesswire.comZura Bio Reports First Quarter 2025 Financial Results and Recent Corporate UpdatesMay 9, 2025 | standard-journal.comSAfter losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gainApril 24, 2025 | finance.yahoo.comZura Bio price target lowered to $3 from $5 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comZura Bio (ZURA) Gets a Buy from GuggenheimMarch 31, 2025 | markets.businessinsider.comHopeful Week For Insiders Who Bought US$1.01m Of Zura Bio StockMarch 26, 2025 | finance.yahoo.comZura Bio Limited: 2024 Financial Results and Strategic ProgressMarch 25, 2025 | tipranks.comZura Bio Reports Full Year 2024 Financial Results and Recent Corporate UpdatesMarch 25, 2025 | businesswire.comZura Bio to Present at the Leerink Partners Global Healthcare ConferenceFebruary 24, 2025 | businesswire.comZURA stock touches 52-week low at $1.44 amid market shiftsFebruary 11, 2025 | msn.comDown -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)January 24, 2025 | zacks.comWe Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business GrowthJanuary 22, 2025 | finance.yahoo.comZura Bio Highlights Strategic Goals and Clinical AdvancesJanuary 13, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerThese 3 Rare Earth Stocks Are Surging Alongside MP MaterialsBy Leo Miller | July 19, 2025View These 3 Rare Earth Stocks Are Surging Alongside MP MaterialsForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffWhy Lucid’s 36% Rally on Uber Deal Could Be a Game-ChangerBy Leo Miller | July 22, 2025View Why Lucid’s 36% Rally on Uber Deal Could Be a Game-ChangerCING, ZURA, COYA, and TCRX Company DescriptionsCingulate NASDAQ:CING$5.10 -0.08 (-1.54%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.69 -0.41 (-8.12%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Coya Therapeutics NASDAQ:COYA$6.09 +0.14 (+2.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.06 -0.04 (-0.57%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.TScan Therapeutics NASDAQ:TCRX$1.62 -0.12 (-6.90%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.58 -0.05 (-2.78%) As of 08/1/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Zura Bio NASDAQ:ZURA$1.50 +0.10 (+7.14%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.50 0.00 (0.00%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.